Core Viewpoint - 科济药业 is actively repurchasing its shares to enhance shareholder value while continuing to develop innovative CAR-T therapies for unmet clinical needs [1][2] Group 1: Share Repurchase Activity - On November 6, 科济药业 announced the repurchase of 1.734 million shares at a price range of HKD 14.350 to HKD 15.8, totaling HKD 26.3078 million [1] - In the past month, the company has conducted three repurchase activities, acquiring a total of 2.189 million shares for a cumulative amount of HKD 33.9758 million [1] - The company has a repurchase plan allowing it to buy back up to 1% of its total issued shares in the open market [1] Group 2: Company Overview and Product Pipeline - 科济药业 is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [1] - The company has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [1] - The all-human BCMA autologous CAR-T product,赛恺泽, has been approved for marketing in China, while the Claudin18.2 autologous humanized CAR-T product,舒瑞基奥仑赛, is the first CAR-T product for solid tumors to submit a new drug application globally [1] Group 3: Recent R&D Achievements - On November 3, 科济药业 announced new clinical data for its universal CAR-T products, CT0596 and CT1190B, showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma and non-Hodgkin lymphoma, respectively [2] - As of June 30, 2026, the company reported cash and cash equivalents exceeding HKD 1.26 billion, indicating a strong financial position to support ongoing operations and share repurchase plans [2] - The management expressed commitment to maintaining the share repurchase program, adjusting it based on market conditions to further protect shareholder interests [2]